Alessandra Balduzzi1, Vincenzo Bagnardi2, Nicole Rotmensz3, Silvia Dellapasqua4, Emilia Montagna4, Anna Cardillo4, Giuseppe Viale5, Paolo Veronesi6, Mattia Intra7, Alberto Luini7, Giancarlo Pruneri5, Giuseppe Mastropasqua8, Aron Goldhirsch9, Marco Colleoni4. 1. Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: alessandra.balduzzi@ieo.it. 2. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, Unit of Biostatistics, Epidemiology and Public Health, University of Milan-Bicocca, Milan, Italy. 3. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. 4. Division of Medical Senology, European Institute of Oncology, Milan, Italy. 5. Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Italy. 6. School of Medicine, University of Milan, Italy; Molecular Senology Unit, European Institute of Oncology, Milan, Italy. 7. Division of Senology, European Institute of Oncology, Milan, Italy. 8. Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. 9. Vice-Scientific Director, European Institute of Oncology, Milan, Italy.
Abstract
INTRODUCTION: The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear. PATIENTS AND METHODS: We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR < 1%, and group 2 with ER/PgR 1% to 10%. RESULTS: Group 1 (ER/PgR < 1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P = .16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P = .13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P = .061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P = .36) and OS (P = .30). CONCLUSION: The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR <1% group. Further studies are needed to identify the appropriate clinical approach in this subset of patients with low ER/PgR expression (ER/PgR 1%-10%), HER2-negative early breast cancer.
INTRODUCTION: The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancerpatients is still unclear. PATIENTS AND METHODS: We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR < 1%, and group 2 with ER/PgR 1% to 10%. RESULTS: Group 1 (ER/PgR < 1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P = .16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P = .13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P = .061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P = .36) and OS (P = .30). CONCLUSION: The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR <1% group. Further studies are needed to identify the appropriate clinical approach in this subset of patients with low ER/PgR expression (ER/PgR 1%-10%), HER2-negative early breast cancer.
Authors: Rachel Yoder; Bruce F Kimler; Joshua M Staley; Kelsey Schwensen; Yen Y Wang; Karissa Finke; Anne O'Dea; Lauren Nye; Manana Elia; Gregory Crane; Richard McKittrick; Robert Pluenneke; Sheshadri Madhusudhana; Larry Beck; Anuj Shrestha; Larry Corum; Mark Marsico; Shane R Stecklein; Andrew K Godwin; Qamar J Khan; Priyanka Sharma Journal: NPJ Breast Cancer Date: 2022-07-11
Authors: Halei C Benefield; Emma H Allott; Katherine E Reeder-Hayes; Charles M Perou; Lisa A Carey; Joseph Geradts; Xuezheng Sun; Benjamin C Calhoun; Melissa A Troester Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: H Ghebeh; S Al-Khaldi; S Olabi; A Al-Dhfyan; F Al-Mohanna; R Barnawi; A Tulbah; T Al-Tweigeri; D Ajarim; M Al-Alwan Journal: Br J Cancer Date: 2014-08-12 Impact factor: 7.640
Authors: David Hicks; Patrizia Dell'Orto; Mary Falzon; Kirsten D Hoff; Yaron Y Levy; Loralee McMahon; Keith Miller; Leila Russo; Giuseppe Viale Journal: Appl Immunohistochem Mol Morphol Date: 2017 May/Jun